Tuesday 9/23 Insider Buying Report: SAVA, BCDA

Recent SEC filings indicate significant insider buying, with Cassava Sciences (SAVA) CEO Richard Barry purchasing 237,941 shares for $534,743 at $2.25/share, marking his first buy in a year, which coincided with SAVA's 19.8% gain on Tuesday. Simultaneously, BioCardia (BCDA) Director Simon H. Stertzer acquired 398,400 shares for $498,000 at $1.25/share, contributing to BCDA's 11.7% increase, suggesting executive confidence is driving positive market reactions for both companies.

Analysis

Significant insider buying has been reported at two distinct biotechnology firms, Cassava Sciences (SAVA) and BioCardia (BCDA), signaling strong executive conviction and triggering positive market reactions. At Cassava, CEO Richard Barry executed his first purchase in the past year, acquiring 237,941 shares for $534,743, a move that preceded a 19.8% single-day stock price increase and gave the CEO an intraday unrealized gain of 28.6%. This type of infrequent, large-volume purchase by a CEO is often viewed as a particularly strong bullish indicator. Concurrently, BioCardia Director Simon H. Stertzer continued his pattern of accumulation, purchasing 398,400 shares for $498,000. This adds to four other purchases over the last year, though his latest buy at $1.25 per share is notably below his previous average cost of $2.03, suggesting a potential averaging-down strategy. In response, BioCardia's stock also climbed 11.7%, reinforcing that the market is interpreting these insider transactions as a strong vote of confidence in the companies' future prospects.

Key Decisions for Investors

• The substantial insider purchases at both SAVA and BCDA are strong bullish signals that warrant closer examination of both companies as potential long opportunities.
• Investors should weigh the SAVA CEO's first purchase in a year as a potentially more significant catalyst, given the stock's immediate and sharp 19.8% rally.
• For BCDA, the director's consistent buying is positive, but the lower purchase price of $1.25 compared to his $2.03 average cost suggests investors should evaluate if this is an opportunistic buy in an undervalued asset or a sign of averaging down on a riskier position.
• Monitor both tickers for follow-through momentum, as the market's initial positive reaction to these insider signals could indicate the beginning of a sustained upward trend.